The primary aim of the present study was to investigate if dapagliflozin, the most frequently used SGLT‐2 inhibitor in the Nordic countries,7 was associated with risks of MACE, HHF and all‐cause mortality compared with DPP‐4 inhibitors in a broad unselected population with T2D using nationwide data from Denmark, Norway and Sweden. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.